Education
About Us
Working with TipRanks
Follow Us
Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
1167 Stock Chart & Stats
HK$7.63
HK$0.04(3.17%)
At close: 4:00 PM EST
HK$7.63
HK$0.04(3.17%)
Day’s Range― - ―
52-Week RangeHK$1.81 - HK$11.80
Previous CloseN/A
Volume546.60K
Average Volume (3M)7.94M
Market Cap
HK$4.80B
Enterprise ValueHK$3.49B
Total Cash (Recent Filing)HK$1.07B
Total Debt (Recent Filing)HK$143.01M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 25, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.00
Price to Sales (P/S)5.94
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong LiquidityA cash-rich balance sheet with negative net debt provides durable runway for clinical programs and reduces immediate refinancing pressure. This liquidity supports ongoing trials, partner negotiations and milestone-driven development over the next several months without forced asset sales or urgent dilutive raises.
Improving Gross MarginsA positive gross profit margin signals the business can generate margin on revenues, indicating improving product or service economics. Over 2–6 months this supports operating leverage potential as revenue recovers, making path-to-profitability more achievable if operating expenses are controlled.
Diversified R&D PipelineAn internally discovered plus in-licensed pipeline and external collaborations provide multiple development pathways and de-risk clinical R&D. Structurally this gives several value inflection points, options for out-licensing, and reduced single-asset dependency over the medium term.
Bears Say
Persistent Net LossesOngoing net losses indicate the company is not yet self-sustaining and will likely need external funding to progress clinical programs. Over months this trend can dilute shareholder value, constrain strategic choices, and pressure management to prioritize short-term financing over long-term value creation.
Negative Operating Cash FlowConsistent negative operating and free cash flow undermine the firm's ability to internally fund trials and commercialization. This structural cash burn increases dependence on external financing, heightening refinancing and dilution risk and limiting flexibility in prioritizing research programs.
Declining Equity BaseA shrinking or historically negative equity base weakens financial resilience and can constrain access to debt or favorable partner deals. Over a multi-month horizon this erosion may increase covenant risk, raise funding costs, and limit the company’s ability to pursue opportunistic licensing or M&A moves.
Jacobio Pharmaceuticals Group Co., Ltd. News
1167 FAQ
What was Jacobio Pharmaceuticals Group Co., Ltd.’s price range in the past 12 months?
Jacobio Pharmaceuticals Group Co., Ltd. lowest stock price was HK$1.81 and its highest was HK$11.80 in the past 12 months.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s market cap?
Jacobio Pharmaceuticals Group Co., Ltd.’s market cap is HK$4.80B.
When is Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date?
Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date is Mar 25, 2026 which is in 29 days.
How were Jacobio Pharmaceuticals Group Co., Ltd.’s earnings last quarter?
Jacobio Pharmaceuticals Group Co., Ltd. released its earnings results on Aug 29, 2025. The company reported -HK$0.091 earnings per share for the quarter, beating the consensus estimate of -HK$0.192 by HK$0.102.
Is Jacobio Pharmaceuticals Group Co., Ltd. overvalued?
According to Wall Street analysts Jacobio Pharmaceuticals Group Co., Ltd.’s price is currently Overvalued.
Does Jacobio Pharmaceuticals Group Co., Ltd. pay dividends?
Jacobio Pharmaceuticals Group Co., Ltd. does not currently pay dividends.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate?
Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate is -0.01.
How many shares outstanding does Jacobio Pharmaceuticals Group Co., Ltd. have?
Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding.
What happened to Jacobio Pharmaceuticals Group Co., Ltd.’s price movement after its last earnings report?
Jacobio Pharmaceuticals Group Co., Ltd. reported an EPS of -HK$0.091 in its last earnings report, beating expectations of -HK$0.192. Following the earnings report the stock price went up 9.299%.
Which hedge fund is a major shareholder of Jacobio Pharmaceuticals Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1167
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobio Pharmaceuticals Group Co., Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
301.85%
12-Months-Change
Fundamentals
Return on Equity
-5.08%
Trailing 12-Months
Asset Growth
0.29%
Trailing 12-Months
Company Description
Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.
Technical Analysis
Viva Biotech Holdings
―
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―
Options Prices
Currently, No data available
---